Detalhe da pesquisa
1.
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma.
Hematol Oncol
; 41(3): 578-582, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36043430
2.
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.
Br J Haematol
; 192(3): 568-576, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33341940